share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne

SEC announcement ·  Jun 24 17:36
Summary by Moomoo AI
CRISPR Therapeutics COO Julianne Bruno sold 3,366 shares of the company's common stock on 06/21/2024, as per the latest SEC filings. The shares were sold at a price of $56.09 each, totaling approximately $188,798.94. This transaction followed an acquisition of 7,000 shares on 06/20/2024 through the exercise of derivative securities. After these transactions, Bruno directly holds 6,745 shares of CRISPR Therapeutics. Additionally, Bruno has an indirect beneficial ownership of 7,088 shares through The Julianne Bruno 2022 GRAT. The transactions have been reported as completed.
CRISPR Therapeutics COO Julianne Bruno sold 3,366 shares of the company's common stock on 06/21/2024, as per the latest SEC filings. The shares were sold at a price of $56.09 each, totaling approximately $188,798.94. This transaction followed an acquisition of 7,000 shares on 06/20/2024 through the exercise of derivative securities. After these transactions, Bruno directly holds 6,745 shares of CRISPR Therapeutics. Additionally, Bruno has an indirect beneficial ownership of 7,088 shares through The Julianne Bruno 2022 GRAT. The transactions have been reported as completed.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more